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ABSTRACT
Nanomedicine holds incredible promise for clinical diagnostic and therapeutic
applications. Nanoparticles (NPs) are widely used in this field due to the tunability of their
characteristics, including size, shape, surface charge, and material composition. These
customizable characteristics allow NPs to be effectively used in a variety of remedial
applications. When NPs are administered within the body, they are exposed to a many
different types of proteins that bind to their surface. These bound proteins heavily influence
the biological response to the NPs. The NPs’ composition and surface chemistry determine
the extent, as well as the specificity, of the proteins binding to the particle. Protein binding
is one of the main determinants of bioavailability and biodistribution of NPs within the
body; engineering the NP surface to direct the protein-particle interactions is crucial for
therapeutic efficacy, as well as limiting toxicity.
To further investigate protein adsorption on NPs, polymeric NPs were synthesized
with encapsulated fibroblast growth factor (FGF) using emulsion methods and were
exposed to mouse serum for varying amounts of time (3 hours and 20 hours). FGF was
chosen as the therapeutic agent because its intracellular delivery initiates a negative
feedback loop that leads to reduced cancer cell migration and proliferation. To test the
effects of particle composition and surface coatings, polylactic co-glycolic acid (PLGA)
and alginate were used to generate two particle types, and polyethylene glycol (PEG) was
separately included to form two additional particle types. Particle size and surface charge
were measured after protein exposures, as well as the concentrations of protein existing
within solution and on the NP surface. This study concluded that the use of PEG
dramatically decreased the concentration of proteins adsorbed to the surface of PLGA NPs,
cutting the number of proteins approximately in half. Additionally, the concentration of
NPs and protein present in solution affect the protein adsorption kinetics, likely due to the
changes in the number of interactions that take place and transport of proteins to the NP
surface. As proteins bind to the surface of the particle, the particle hydrodynamic size
increases slightly, which can clearly be seen after 20 hours of exposure. This new
knowledge of material-specific protein adsorption for polymeric NPs that have
encapsulated growth factor sheds light on the biological response likely seen when the
FGF-encapsulating nanotechnology is translated in vivo for cancer treatment. Efficacious
and controlled drug delivery for disease treatment depends heavily on the NP-protein
complexes that form, and the interactions studied here create a solid foundation for a new
potential cancer treatment.
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CHAPTER 1: BACKGROUND AND MOTIVATION
1.1. Introduction
Nanotechnology is an emerging field with incredible promise for solving some of
the world’s most pressing issues, specifically ones related to human health that have taken
harsh tolls on the average person’s lifespan. The term nanotechnology itself refers to the
application of structures that are engineered typically by either top-down or bottom-up
development methods and are between 1-100 nanometers (nm) in size. Within scientific
literature, the term “nano” commonly also describes structures that are several hundred nm
in size. These nanostructures can be used as diagnostic tools, as well as therapeutic delivery
systems; in this sense, this type of technology is referred to as nanomedicine [1]. As it
currently stands, nanoparticles (NPs) dominate nanomedicine due to the tunability of their
characteristics; they are used in imaging, biosensing, tissue engineering, and drug delivery,
amongst many other categories of clinical practice and research application [1], [2]. NPs
are special in the fact that they have the ability to uniquely move through the human body
compared to larger materials. NPs used in drug delivery studies show promising results
due to their ability to be more precise in the delivery of the drug, along with their capability
for controlled drug release once at the intended site. Nanodrugs also have a higher oral
bioavailability because they are small enough to be included in the typical uptake
mechanisms of absorptive endocytosis [2]. Some NPs can be designed to have low or even
no toxicity when used in drug therapies, which plays a key role in the treatment being able
to be used clinically with people [1]. For example, several types of COVID-19 vaccines
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have been successfully adopted and make use of lipid nanoparticles for the delivery of
mRNA [3].
As NPs are used as drug delivery systems, the interactions between the body and
the particles dictate their fate, inherently affecting their efficacy through both their
biodistribution and bioavailability. These interactions are driven by proteins that adsorb to
the NP surface. These proteins affect the duration of circulation for the NP, depending on
if it is endocytosed immediately upon administration or later within the body. Being able
to understand these protein adsorption kinetics allows for intentional surface modification
to give the NP the highest probability of evading the immune system and arriving at its
target site for successful drug delivery. The delivery of NPs to their target sites is incredibly
complex, with the application dictating the design of the NP’s characteristics. For example,
currently under research in the Biomedical Nanotechnology and Biomaterials Lab at the
University of Vermont are NPs used to eliminate biofilm infections that are seen with
bacterial keratitis. This treatment requires the NPs to penetrate the tortuous polysaccharide
matrix of the biofilm to reach the bacteria cells inside. Another example under research
within this lab is the intracellular delivery of fibroblast growth factor 2 (FGF-2) for the
treatment of cancer, which requires particles to traverse multiple biological barriers without
releasing their payload until they get to the interior of the cancerous cells. These two
projects demonstrate the important influence that protein adsorption has on a particle’s
ability to navigate the body in a way that allows for it to be efficacious. This thesis work
aims to highlight how different particle materials and surface coatings affect the protein
adsorption rates to the particle, as well as the overall characteristic changes that the NP
2

undergoes as NP-protein complexes are formed, both of which dictate the fate of the NPs
and the therapeutic agents that they are delivering.
When choosing what type of material to use for NPs involved in drug delivery, two
important points that must be considered are the biophysical and the biochemical properties
of the drug that is on the surface or encapsulated in the NP. Following this, the toxicity of
the NP and its constituents needs to be accounted for [4]. NPs are often modified on their
interior or surface to aid in their efficacy. In particular, modifying the surface of the
particles can help improve the bioavailability and solubility of delivered drugs, and can
lead to an increase in the overall therapeutic effect [5], [6]. As more material components
are added into/onto the NPs, the characteristics of this nanotechnology are affected, which
can lead to improved efficacy or unintended side effects. Therefore, each designed
nanomedicine must be individually studied for an understanding of its effects and
usefulness.
One of the most widely investigated types of particles are gold (Au) NPs, due to
their unique optical and physical properties. Au NPs can be synthesized in near
monodispersed sizes, interact strongly with light, can emit heat or electrons under the right
conditions, and can be easily chemically modified at their surface. One example of their
use is photothermal therapy whereby light is absorbed and heat is emitted, which can be
used to either destroy cells in the surrounding area, or to initiate drug release. Further, since
Au NPs can be used for both diagnosis and therapy, they fall into the category of theranostic
agents [7].
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NP size is a critical parameter in their properties, interaction with external stimuli
such as light, and the interaction of the particles with cells and biological barriers. Au NP
size is a crucial characteristic in regard to using light in diagnostic and therapeutic
applications because the size of the particle affects its surface plasmon resonance (SPR).
SPR is a process by which the electrons of the particle resonate in response to
electromagnetic radiation. This interaction between the radiation and electrons causes some
of the light to be absorbed, as well as some of it to be scattered to the surrounding areas
[7]. Changing the size of the Au NPs can change the plasmonic resonance to shift from 520
to 800 nm, and even up to 1200 nm in the case of particles that have complex shapes [8].
Eustis et al. demonstrated how the optical properties of spherical Au NPs drastically change
when anisotropy—like a nanorod—is added to the NPs. Au nanorods increase the intensity
and wavelength maximum of the sample as the aspect ratio (length divided by the width)
of the rod increases. Creating a NP that has the ability to absorb more light intensity leads
to an enhancement in the electric field surrounding the particle, which can be very
important in various applications [9].
Another notable characteristic of NPs is that their surface area is inversely
proportional to their size. This creates a large surface area to volume ratio, meaning that
even though a singular particle has a very small volume, there is much more space on its
surface for a wide variety of uses. The surface is utilized for drug loading, conjugation, and
gene/biological moiety binding. These types of surface modifications can increase the NPs
solubility, stability, and pharmacokinetic behaviors, amongst other types of characteristics
that determine the fate and efficacy of the particle [10].
4

The smaller the NP, the larger the surface area to volume ratio, but going smaller
is not always the best option. As previously identified, particle size and material are going
to be chosen depending on application, which has been clearly highlighted in cancer
diagnostic uses of NPs. For photothermal therapy, a smaller particle size is preferred
because the light is mostly absorbed by the NP, which allows for more heat conversion and
destruction of cells. However, for photoimaging, a larger particle size is preferred because
larger particles have an associated increase in light scattering; this scattering allows for
better imaging results [7], [11].
Another aspect to consider in regard to sizing and available surface area is the
opportunity of interaction between the body’s cellular environment and the NPs. The
biological response tends to scale with the surface area of a particle for numerous reasons,
but one important reason is because the surface is the location where protein adsorption
occurs. For example, when NPs are exposed to a biological environment like serum or
plasma, smaller NPs, which have a larger surface area to volume ratio, have more proteins
bound to them compared to larger particles, when normalized for total volume [7]. As
proteins bind to the surface of the NP, this protein coating is typically called a “corona.”
Once the corona is formed, there now exists NP-protein complexes—instead of just
singular NPs—within the biological environment. The biological response is heavily
influenced by the formed complexes, which are dependent on the NPs’ composition and
surface chemistry; these attributes of the NP determine the extent, as well as the specificity,
of the protein binding to the particle. Working to control what is happening at the NP
surface is crucial for therapeutic targeting because protein binding is one of the main
5

variables that dictates the biodistribution of the NPs within the body [12]. Being able to
understand the NP-protein complexes allows for protein binding manipulation through NP
modification, which would in turn lead to a more controlled biodistribution and
bioavailability of said NPs [12]. Looking at Au NPs interacting with plasma in particular,
the NP’s longevity within the bloodstream is dependent on the plasma profile at its surface.
While being used in therapeutic applications, a NP’s efficacy is dependent on the time that
it spends in the bloodstream [13]. As opsonins tag the NP surface, the NP becomes easily
recognized by the immune cells as “foreign” or “non-self,” which is a part of the
reticuloendothelial system (RES). This tagging of NPs will eventually determine how the
NPs are internalized, which subsequently affects the fate of the NPs within the body
including their deliverable cargo. The rate of clearance, the route, the volume of
distribution within the bloodstream and the body, and the organ disposition are all
dependent on the protein corona and its composition. All of these aspects also affect the
particle’s active targeting abilities, toxicity, and induced off-target effects [14].
When it comes to different approaches for designing a NP that has the ability to
circulate longer within the body without detection, polyethylene glycol (PEG) is a common
resort. PEG is biocompatible and hydrophilic, which effectively works in the favor of NP
drug delivery to help make the NP surface “look” like water [15], [16]. Studies have found
that applying a coating of PEG to the outside of NPs, which is called PEGylation, prolongs
the NPs’ circulation time in the blood, improves colloidal stability, and increases tumor
accumulation [17]–[19]. This is due to PEG’s ability to reduce cell surface binding, which
is what drives NP endocytosis. Endocytosis can be further broken down into its different
6

pathways of phagocytosis, pinocytosis, and clathrin-dependent and clathrin-independent
receptor-mediated endocytosis (in order based on involvement from largest to smallest
particle types, respectively) [15], [20]. The chosen pathway that internalizes the NP will
depend on the cell type involved and the properties of the NP, which is why optimizing NP
characteristics is paramount [15]. PEGylation is essentially a form of stealthy “blanket”
that works to hide the NP from those pathways that operate within the cellular and immune
responses. Although the RES will eventually identify and react to the particle, the time in
which this process takes place is much longer than if the NP had no PEG coating at all [7].
Castellanos-Rubio et al. were able to clearly demonstrate that the uptake rate of NPs is
significantly decreased as the molecular weight (MW) of PEG is increased [21]. NPs that
do not have a PEG coating tend to be unstable and are commonly internalized by
macrophages while circulating throughout the blood. An in vivo study using rats conducted
by De Jong et al. supports this phenomenon that Au NPs with no PEG coating are rapidly
cleared upon intravenous injection into mice [22]. However, with particles that have a PEG
coating, the ability to be dispersed in solution is amplified because the PEG shields the
NP’s own surface charge, allowing for less agglomeration and more spatial coverage within
the blood. Additionally, instead of the NP fate being dependent on the NP/protein
interactions, it becomes dependent on the grafted PEG chains and the cellular membrane,
which is a much easier microenvironment to control [23].
Endocytosis of NPs is not always a negative event, in fact, active targeting of NPs
actually depends on it. During active targeting, NPs have ligands of specific biomarkers—
like antibodies, aptamers, peptides, and vitamins—conjugated to their surface. The goal is
7

that once the NPs reach their target area, the ligands interact with their matching receptors
on the cells there, which allows for endocytosis of the NP and the release of the drug inside
of the cell. The setup of active targeting typically increases the chances of the NP being
internalized inside of the desired cells compared to passive targeting [24]. The key goal is
for the NPs to avoid internalization until they reach their target site; if they do not make it
to their target site, then the treatment has poor efficacy. Using active targeting prevents offtarget effects, since the drug release takes place only at the target site. This decreases the
possibility that off-target tissues and organs would be affected by the active encapsulated
drug. Active targeting also reduces the dose-limited adverse effects of the drug being used
because it is a much more direct form of treatment [25].
Alternatively, passive targeting is not nearly as specific as active targeting.
Assuming that the endothelium is in a form of diseased state, which is very common for
areas that have tumors, passive targeting takes advantage of the cell’s permeability within
the unhealthy tissue. When hypoxia is occurring because of tumor growth, the tumor
responds by increasing the amount of vasculature within its surrounding areas. These
newfound vessels are typically quite leaky, which allows for particles traveling through the
vessels to make their way through the loose barrier and into the tumor microenvironment
[25], [26]. Another component that allows for successful passive targeting is that tumors
lack normal lymphatic drainage that is seen in healthy tissue as a form of maintenance; this
contributes to NP retention within the diseased tissue [25], [27]. The increase in leakiness
of the vessels and the lack of lymphatic drainage seen within the tumor microenvironment
is known as the enhanced permeability and retention (EPR) effect [28]. Many forms of
8

passive targeting using NPs rely on the EPR effect, as well as stealth coatings like PEG to
get the NPs to the area of interest. Multiple studies have been conducted to investigate the
effects of passive targeting while using nanocarriers bearing molecules of interest; the
studies very commonly used PEG as their ligand coatings, compared to cell-specific
ligands that are used in active targeting [29]–[31]. On top of the body’s response to the
NP’s coating and the intensity of the EPR effect, other variables that dictate the NPs ability
to effectively deliver its drug are blood flow, tumor cell density, intratumoral pressure
gradients, and the extracellular matrix (ECM) present. As each of these components
change, the NPs efficacy changes as well [32].
For both active and passive targeting, size continues to be an important factor to
consider. The size of the NP affects the permeation and retention within the tumor, which
means that its ability to stay within the target site depends on the fenestrations in the tumor
vessels. Typically, the sizes of these openings range from 200-800 nm, so for targeting
purposes, particle size would ideally be within this range [26], [33]. On the other hand, as
NPs make their way through vasculature, they are at risk for being removed from the
bloodstream through renal excretion or the RES. These immune responses take place if the
particles are less than or greater than 6 nm, respectively. Due to these size constraints, ideal
NPs used in targeting are usually between 20-200 nm and involve surface modifications to
avoid both removal systems [34].
After the NP successfully arrives at the targeted tissue site, delivering the drug
exactly where it needs to go in the cell is the next battle. The two types of locational drug
delivery are extracellular and intracellular, both of which are used depending on a wide
9

range of requirements in each individual treatment scenario. It is more common in cancerrelated drug delivery work that the drugs being encapsulated need to be delivered
intracellularly compared to extracellularly. Numerous key disease-related targets—like
transcription factors and RAS proteins—reside within the cell, usually in the cytosol or the
nucleus [32], [35]. For cancer in particular, these targeted proteins are often oncogenic
drivers, and are usually involved in treatment resistant mechanisms [36]. Being able to get
the drug to the internal locations that house these proteins can be complicated; this is where
intracellular delivery comes into play. Intracellular drug delivery is required when the drug
being used is not membrane permeable. In order to get the NP and drug inside of the cell,
a common method is to attach a targeting ligand that matches with a targeted cell surface
receptor to the very end of the PEG that is on the NP surface; when the ligand binds to its
receptor, this triggers cellular internalization of the NP and the encapsulated drug [18].
Once the NP and the drug are endocytosed, the next issue to consider is how the protein
will get into the cytosol, or even into the nucleus. Before nanocarriers of proteins, it was
very common for proteins to get trapped in the endosome and then be degraded by
cathepsins that are present in the lysosomal and endosomal pathway [37]. This resulted in
low amounts of protein reaching the cytosol, making the treatment much less effective [38].
Using NPs as part of the drug delivery system allows for protection of the drugs from
degradation in the endosome; this can be accomplished through NP size, charge, and
attached ligand modifications, all of which can work to encourage cellular uptake,
endosomal escape, and the release of the drug from inside of the NP to the inside of the
cell [39].
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The process by which NPs escape the endosome must be considered since the NPs
cannot directly cross the endosomal membrane on their own. Common mechanisms for
endosomal escape include the following: pore formation via membrane tension and line
tension manipulation; protonation to increase ion and water flow into the endosome to
cause rupture; destabilizing the membrane via the use of agents—like fusogenic proteins,
lipids, and peptides—to encourage cargo release; and the promotion of fusion between
liposomes and the endosomal membrane through the use of cleaved PEG-lipids [32], [40]–
[42]. Depending on the mechanism used, the NP will be altered since each mechanism
requires a different approach; these choices will affect varying attributes of the NP, which
will need to be accounted for and verified through various techniques.
Once particle parameters have been identified and the NPs are synthesized, the NPs
need to be characterized. As one of the most important determinants of NP fate within the
body, NP size is usually characterized first. One common method for analyzing the size
and homogeneity of a sample of NPs is dynamic light scattering (DLS), which is sometimes
also referred to as photon correlation spectroscopy (PCS). DLS is non-invasive and works
by exposing the sample to a monochromatic wave of light as a detector detects the
fluctuations in the intensity of the scattered light given off by the sample’s contents. The
diffusion behavior of the particles in the sample will have an associated diffusion
coefficient, which depends on the NP’s size, shape, and related Brownian motion. The
diffusion coefficient is used with the Stokes-Einstein relationship to calculate the
hydrodynamic radii of the NPs, which is reported as the Z-Average size with the use of a
Zetasizer [43]–[45]. The Z-average size is a cumulative mean measurement that includes
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all that composes the NP structure from inner core to the outermost surface as the NP
diffuses within a fluid; this size also includes any protein that has been adsorbed to the
surface [44], [45]. It is important to note that to simplify measurements, NP size through
DLS is defined using a concept called “equivalent spheres.” This concept exists on the
basis that the sample’s particle size is defined by the diameter of a sphere that has the same
properties, like mass and volume, as the actual particles being measured. This concept
works very well for regularly shaped spherical particles but does not always work well for
irregularly shaped NPs that have sizes that significantly vary from one dimension to the
next. Different types of measurement instruments use different equivalent sphere models,
leading to differing results in particle diameters for the same sample [44]. The results of
DLS also provide a polydispersity index (PDI) value, which is an indication of the NP’s
quality with respect to the size distribution. In other words, the PDI value indicates the
degree of non-uniformity of a distribution, which is particle size in this case [20], [46]. A
perfectly uniform sample will have a PDI of 0.0, whereas a sample with a PDI greater than
0.7 indicates that there is a broad size distribution and DLS might not be the most suitable
measuring technique due to the nonuniformity within the suspension [45], [46].
Another predominant feature of NPs is their surface charge, which is commonly
characterized using a zetasizer. The surface charge heavily dictates the interactions of the
NPs with the biological milieu, which is why this component is so crucial to know. The
surface charge has been termed zeta potential, or sometimes is also referred to as
electrokinetic potential [47]. More specifically, this potential is the difference in charge,
measured in millivolts (mV), that exists between the NP’s surface and the bulk of the liquid
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that the NP is immersed in [48], [49]. Measuring the zeta potential works by having two
beams of light; one beam is a reference beam and the other is aimed at the sample. The
particles within the sample scatter this light during electrophoresis, creating different
frequencies. A frequency shift is calculated based on comparing the frequencies from the
sample’s scattered light to the reference light beam. This shift is proportional to the NP’s
speed, which is also called the Dopler shift. The magnitude of the NP’s velocity is deduced
from the Doppler shift. From here, a series of calculations are performed by the instrument
to solve for the zeta potential of the NPs. This type of zeta potential measurement style is
called electrophoretic light scattering. There are other ways to measure the zeta potential
of particles, but this approach is very commonly used in conjunction with DLS
measurements, making it very favorable. A user can conduct sample readings on one
singular instrument and acquire two critical NP characterization results from it [47].
Taking into consideration the size parameters, material characteristics, and
surface modifications, four different polymeric NPs will be synthesized with encapsulated
FGF-2 using emulsion techniques. FGF-2 is being used as the encapsulated therapeutic
agent because upon intracellular delivery, it initiates a negative feedback loop that leads to
a reduction in cancer cell migration and proliferation [50]. Two of the particle types will
be synthesized using polylactic co-glycolic acid (PLGA) and alginate. Polyethylene glycol
(PEG) will separately be included to form two additional particle types. These synthesized
particles will each be exposed to mouse serum and the protein within the experiment will
be measured as it remains in solution and/or adsorbs to the particles’ surfaces. Average
surface charge and hydrodynamic size of each type of particle will be read and overall
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trends of protein adsorption will be analyzed and discussed. The results of these
experiments will help establish the following two concepts; how the protein adsorption
kinetics change as materials and surface coatings change, and how the NP is physically
affected as protein adsorbs onto its surface.
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CHAPTER 2: MATERIALS AND METHODS
2.1. Materials
Calcium chloride dihydrate (CaCl2), Span 80, Tween 80, light mineral oil, 2propanol,

trehalose,

human

FGF-2,

20

nm

gold

nanoparticles

(Au

NPs),

Tris(hydroxymethyl)aminomethane, mouse serum (40-75 mg/mL), phosphate buffered
saline (PBS), and poly(D,L-lactide-coglycolide) (PLGA) 50:50 (MW 38,000~54,000 Da)
were purchased from Sigma Aldrich. Poly(lactide-co-glycolide) 40 kDa - poly(ethylene
glycol) methyl ether 5 kDa (PLGA40K- MPEG5K) was purchased from Nanosoft
Polymers. Alginate powder (Manugel MW 170 - 240 kDa) was purchased from FMC
Biopolymer. Alginate-PEG was synthesized using the manugel from FMC Biopolymer and
amino end-capped methoxy poly(ethylene glycol) (mPEG-NH2) (MW 550 Da) from
Laysan Bio. Acetone and a bicinchoninic acid (BCA) protein assay were purchased from
Fisher Scientific. Five percent aqueous polyvinyl alcohol (PVA) was purchased from
VWR. All particles were freeze dried with a FreezeZone 2.5 freeze dryer purchased from
Labconco. All size and zeta potential readings were completed using a Zetasizer nano ZS
from Malvern instruments; the folded capillary zeta cells used to hold the samples during
readings were also purchased from Malvern instruments. All experiments that involved the
use of deionized (DI) water used ultrapure water of resistivity 18.2 MΩ cm.
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2.2. Methods
2.2.1 Water in Oil Emulsion Techniques
Calcium-crosslinked alginate and alginate-PEG nanoparticles with encapsulated
FGF-2 (Alg-FGF and Alg-PEG-FGF NPs) were synthesized using a water in oil (w/o)
method. A 25 mL round bottom flask with 6.72 mL of 5% (v/v) Span 80 in mineral oil was
mixed with a stir bar on a stir plate at 1,200 rpm. One mL of 1% w/v alginate in DI water
was pipetted slowly into the round bottom flask, drop by drop. If Alg-PEG-FGF particles
needed to be synthesized, then this step would use alginate-PEG instead of the plain
alginate. One μL of FGF-2 was added to the round bottom flask and the stir bar was then
removed so that the solution could be homogenized for 5 minutes. After homogenizing,
the stir bar was added back into the solution and the solution was stirred at 1,200 rpm again.
Following this, 400 μL of 30% (v/v) Tween 80 in DI water was added dropwise to the flask
and mixed thoroughly for 5 minutes. Five mL of a 0.1 M CaCl2 (MW 147.01 g/mol)
solution was added to the flask drop to drop and mixed for 30 min to complete the
crosslinking process. To stop the reaction of the calcium, 3 mL of 2-propanol was added
to the flask and mixed until fully dispersed. Figure 1 demonstrates this first part of
nanoparticle synthesis. The solution in the flask was then centrifuged for 5 minutes at 4,000
rpm at room temperature (RT) to pellet the particles. The supernatant was decanted into a
labeled waste bottle, and the particles were resuspended in 3 mL of 2-propanol to start the
washing process. The resuspension was centrifuged again, following the same parameters
as before. This propanol wash step took place 3 times total and was specifically used to
wash away any remaining free mineral oil in the sample. The particles were then washed
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3 more times with DI water to wash away any remaining propanol and free salt from the
calcium chloride crosslinking step. The final pellet collected was put in the freezer for 1
day and freeze dried for 2 days. After 2 days of being attached to the freeze drier, the
pellet’s mass was measured to calculate the yield. A visual of the washing/collecting steps
of the protocol can be seen in Figure 2. A more in-depth, step-by-step visual walkthrough
of this w/o protocol can be found in the supplemental material in the “Emulsion Protocols”
section 7.1 as Figure 33.

Figure 1. Synthesizing NPs using w/o emulsion techniques
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Figure 2. Washing and collecting the NPs that were synthesized with w/o emulsion
techniques

2.2.2 Water in Oil in Water Emulsion Techniques
PLGA and PLGA-PEG nanoparticles with encapsulated FGF-2 were synthesized
using a water in oil in water (w/o/w) method. The inner aqueous phase was composed of 1
μL of 1 mg/mL of FGF-2 in 5 mM Tris solution and 399 μL of 1X PBS. The oil phase was
composed of 4 mL of acetone and 100 mg of PLGA 50:50 (MW 38,000~54,000 Da). If
PLGA-PEG-FGF particles needed to be synthesized, then this step used PLGA-PEG
instead of PLGA. Figure 3 demonstrates the creation of these 2 phases. The PLGA required
vortexing in acetone to dissolve. To emulsify the inner aqueous phase, the 400 μL of inner
aqueous phase was poured into the oil phase, immediately sonicated for 60 seconds, and
then vortexed for 60 seconds. The solution was then poured into 7 mL of 1% PVA,
immediately sonicated for 60 seconds, and then vortexed for 60 seconds. Figure 4
demonstrates this first half of the protocol for creating the emulsion. Fifty mL of 0.03%
PVA was then added to an Erlenmeyer flask with an appropriate stir bar that was on a stir
18

plate, which was set to 500 rpm. The mixed PLGA solution was added to this 50 mL of
stirring PVA, and the acetone was evaporated out of solution in the fume hood for 1 hour
using a vacuum pump. A waft test was conducted to confirm that the acetone had been
removed from the solution after the hour had passed. The synthesized nanoparticles were
transferred to a Beckman Coulter centrifuge tube and centrifuged for 15 minutes at 35,000
x g at RT. The supernatant was decanted into a labeled waste container, and the pellet was
resuspended in 25 mL of DI water. The resuspension was centrifuged again using the same
parameters as the previous centrifuge run. This wash step was completed a total of 3 times.
The final pellet collected was put in the freezer for 1 day and then freeze dried for 2 days.
After 2 days of being connected to the freeze drier, the pellet’s mass was measured to
calculate the yield. This second half of the w/o/w protocol focusing on cleaning and
collecting the nanoparticles can be seen in Figure 5. A more in-depth, step-by-step visual
walkthrough of this w/o/w protocol can be found in the supplemental material section 7.1
as Figure 34.

Figure 3. Creating the 2 phases for the w/o/w protocol used for PLGA-FGF and PLGAPEG-FGF NPs
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Figure 4. Creating the emulsion for the w/o/w protocol used for PLGA-FGF and PLGAPEG-FGF NPs

Figure 5. Washing and collecting the PLGA-FGF and PLGA-PEG-FGF NPs synthesized
from the w/o/w protocol
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2.2.3 Protein Exposure
2.2.3.1 Initial Experiments; 3 Hours for Alg-FGF, Alg-PEG-FGF, PLGA-FGF, and
PLGA-PEG-FGF NPs
For exposing all of the synthesized particles to mouse serum, the mouse serum was
separated into aliquots to avoid freeze/thaw cycles. For this experimental setup, aliquots of
100 μL were made and stored in the -20°C freezer. A visual of this aliquoting technique
can be seen in Figure 6; this allowed for only 1 aliquot of serum to be taken out of the
freezer at a time, thawed in the water bath, and used that same day for the particle exposure,
which allowed for the rest of the other protein aliquots to stay frozen.

Figure 6. Creating aliquots of the purchased mouse serum protein solution
Once the aliquots of mouse serum had been made, 1 aliquot was taken out of the
freezer and put into the hot water bath until it was time to be used, which was usually about
15 minutes later. The synthesized particles used in this exposure experiment were
previously synthesized, freeze dried, and resuspended in DI water to make a concentration
of 3 mg of particles per mL. This exposure protocol remained the same for every single
particle, and only 1 type of particle was used at a time (i.e. just PLGA-FGF, or just AlgFGF, but never more than 1 type at once). In the initial stages of this project, particle mass
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was used as a constant for creating resuspensions for protein exposure across all particle
types; however, this led to unclear results, likely due to different particles ranging in size
having significantly different surfaces for protein binding. A new approach was created
and is described later within this section.
Before any serum exposure took place, each triplicate sample—marked A, B, and
C—were read on the zetasizer for the particle’s hydrodynamic size and particle’s surface
charge. In this case, “triplicate” refers to particles that were made the same day, but in 3
different round bottom flasks. Triplicates were made in order to have a supportive
collection of data with enough sample to demonstrate reproducibility. Once all of the
particles were resuspended and size and zeta potential measured at time 0, 800 μL of the 3
mg/mL of synthesized particles were added to a microcentrifuge tube for each triplicate
sample. Four μL of mouse serum was then added to each microcentrifuge tube, which
created a concentration of approximately 62 μg/mL of protein in solution. The 3 tubes were
then put on a tube rotator. A timer was started and the first sample of the exposure was
pipetted from the first triplicate after 2 minutes, which was denoted as data for “A1.” The
pipetted volume from the nanoparticle and mouse serum mixture was 50 μL and was
immediately added to a scintillation vial that was filled with 950 μL of DI water. This 1000
μL solution was vortexed for 5 seconds, placed into a capillary tube via syringe, and size
and zeta potential were read. This process of reading the sample with the zetasizer took
roughly 12 minutes total, which affected how often readings were able to be completed.
The reported values from the zetasizer for particle size and surface charge were plotted
onto a graph over time. Once A1 was done being read, B1 was read using the same
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methods. It is important to note that the tube rotator remained rotating as often as possible
and was only stopped briefly for the 50 μL of sample to be taken from the A, B, or C
triplicate tubes. Readings were carried out until the particle size or the surface charge
leveled off on the graphs; this typically occurred after 3-4 readings for each triplicate,
which was equivalent to roughly 2.5 hours of serum exposure. Figure 7 demonstrates this
exposure and zetasizer reading process. A more annotated figure can be seen as Figure 35
in the supplemental material section 7.2 section.

Figure 7. Exposing synthesized NPs to mouse serum and reading them with the Zetasizer
Nano
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2.2.3.2 Adsorption Isotherm Experiment; 22 Hours with Varying Concentrations of
Au NPs
The protein exposure described above using 3 mg/mL of particles in solution
created graphs with trends that were unable to be completely understood; to combat this, a
protein isotherm experiment was set up using 20 nm Au NPs and mouse serum. Nine
different concentrations of nanoparticles were created using a dilution series. Once the
dilution series was completed, 1.5 mL aliquots were put into tubes labeled 1-10. Tube 1
was composed of stock 20 nm Au NPs, which have a concentration of 6.54*1011
particles/mL. The solution in tube 2 was diluted 1:10 to create a concentration of 6.54*1010
particles/mL. The dilution series was repeated until tube 9 had 6.54*103 particles/mL. Tube
10 was a control sample, so it was composed of only DI water. For tube number and
associated particle concentration, see Table 1. To verify that there was a particle
concentration decrease from tube 1-10, absorbance was read at 525 nm on a
spectrophotometer. The results for this absorbance reading can be seen in Table 6 within
the Results section.

Table 1. Protein isotherm experiment with varying Au NP concentrations
Tube Number

Particle Concentration (NPs/mL)

1

6.54*1011

2

6.54*1010

3

6.54*109
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4

6.54*108

5

6.54*107

6

6.54*106

7

6.54*105

8

6.54*104

9

6.54*103

10

0

To get a baseline of information, size and zeta potential were read for the 20 nm
Au NP stock solution before any protein exposure took place. Once this was completed,
mouse serum was added to each tube to create a concentration of 1 mg/mL of protein. Since
all of the tubes had 1.5 mL of particle solution, 20.37 μL of mouse serum was added to
each tube. The tubes were then put on a tube rotator for 22 hours to allow for adequate
mixing. After 22 hours, the tubes were centrifuged for 1 hour at 15,000 g at RT. The
supernatants from each tube were aliquoted, and a BCA assay was run on them to determine
how much free protein existed within the solution. The pellet consisting of particles and
adsorbed protein was resuspended in DI water and 0.1 mM PBS. The volume of PBS used
in conjunction with the DI water depended on how many particles were in the tube from
the start of the experiment; the goal was to have the same amount of PBS in the
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resuspension as the original NP dilution tubes. Since tube 1 was all NP stock—which has
particles in 100% 0.1 mM PBS—tube 1 would be fully resuspended in 0.1 mM PBS. Tube
2 only required 10% as much PBS since it was a 10x dilution of particles. This dilution
continued until tube 9. All tubes were resuspended in 1.5 mL of solution; the only
difference between the resuspension solutions was how much PBS was present. Since tube
10 was a control sample and only contained protein, that tube had water put in it for the
resuspension step. Once all tubes had their particles resuspended, another BCA assay was
run on an aliquot of each tubes’ contents. This assay showed how much protein was
actually adsorbed to the particle surface. As a control measure, the assay was run with Au
NP dilutions in parallel to the NP dilutions that contained protein to account for any
absorbance that was taking place from the NPs alone. The absorbance values of the NP
dilutions were subtracted from the absorbance values of the wells that had particles and
protein, which allowed for the final values of the samples to be only representative of the
protein present. After the BCA assay was completed, size and zeta potential were read on
the zetasizer for all resuspended particles with adsorbed protein to see how the protein was
affecting the particle’s surface characteristics.

2.2.3.3 Adsorption Isotherm Experiment; 22 Hours with Varying Concentrations of
Protein (Au NPs)
The results of the initial protein isotherm experiment demonstrated that different
concentrations of particles behave differently in solution but did not shed light on the
protein adsorption kinetics as hypothesized. To address this, another protein isotherm
experiment was run, but with varying the concentration of protein instead of the
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concentration of nanoparticles. Using this experiment as a proof of concept, stock 20 nm
Au NPs were used since these particles are very uniform and well characterized. Four tubes
were filled with 1.5 mL of 20 nm Au NP stock particles and labeled A, B, C, and D. Tube
A, B, and C contained 30, 20, and 10 μL of mouse serum, respectively. Tube D was a
control and did not have any serum added to it. The volume of serum added to the tubes
was chosen arbitrarily to simply demonstrate a decrease in protein present within the tubes;
there were no specific protein concentrations that those values were trying to reach. To
ensure that each tube had the same particle concentration within the total volume, the
volumes of each tube were adjusted using DI water. Table 2 below lays out the contents
within each tube. The samples were put on a tube rotator for 22 hours.
Table 2. Tube contents for the protein isotherm experiment with varying protein
concentrations
Tube

Volume of 20
nm Au Stock
(mL)

Volume of
Mouse Serum
(μL)

Total Volume
of DI Water
(μL)

Total volume
in Tube (mL)

A

1.5

30

0

1.530

B

1.5

20

10

1.530

C

1.5

10

20

1.530

D

1.5

0

30

1.530
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After 22 hours, the samples were centrifuged for 1 hour at 15,000 g at RT. The
supernatants from each tube were aliquoted, and a BCA assay was run to determine how
much free protein existed within the solution. The pellet consisting of particles and
adsorbed protein was resuspended in 0.1 mM PBS. Once all tubes had their particles
resuspended, another BCA assay was run on an aliquot of each tubes’ contents. This assay
would show how much protein was actually adsorbed to the particle surface. Since tube D
was just NPs, the absorbance value for this sample was used as the “blank” to be subtracted
from the rest of the sample’s absorbances; like previous BCA work, this step ensured that
the final absorbance value was strictly from the protein present in solution and not any
NPs. After the BCA assay was completed, size and zeta potential were read on the zetasizer
for all resuspended particles with adsorbed protein to see how the protein was affecting the
particle’s surface characteristics.

2.2.3.4 Adsorption Isotherm Experiment; 20 Hours with Varying Concentrations of
Protein (Synthesized NPs)
The proof-of-concept protein isotherm experiment with varying concentrations of
protein rather than varying concentration of particles had results that were much more
definitive in regard to the changes occurring at the particles’ surfaces. Building off that
experiment, a new 20-hour protein isotherm experiment was completed using the
nanoparticles that were synthesized for this whole project (PLGA-FGF, PLGA-PEG-FGF,
Alg-FGF, and Alg-PEG-FGF NPs). Since the 20 nm Au NPs yielded very clean results,
this new experiment aimed to replicate the surface area that was present within that
exposure as close as possible. Stock 20 nm Au NPs have a concentration of approximately
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6.54 x 1011 particles/mL. Given that the average size of these particles was 27.15 nm, there
was roughly 2.72*1014 nm2 of surface area for Samples A-D. Using this value as the
experimental standard for surface area, calculations were done using particle size and
density to estimate how many particles would be necessary to provide the identical surface
area for other particle types. Different emulsion techniques ended with different yields, and
because uniformity across all different types of particles for protein exposure was
preferred, the surface area goal value for each sample was decreased by a factor of 10,
making the total available surface area of each sample approximately 2.72*1013 nm2. The
size of a certain particle type and its density was used to calculate the mass of particles
needed to reach the surface area goal for 30 total samples (10 tubes in triplicate); this meant
that each particle type required a slightly different mass for the experiment since each
particle type had a different size and density. An average size and mass breakdown for each
particle type used for protein exposure can be seen in Table 3. The total mass of particles
was then measured for the particle type, added to 45 mL of DI water, and mixed thoroughly.
This NP solution was aliquoted into 30 tubes consisting of 1.5 mL each. Mouse serum was
then added to each tube depending on the desired concentration. Table 4 below shows the
concentrations in each triplicate tube, ranging from 0-5 mg/mL, as well as how much
volume of mouse serum was added to the sample to obtain that protein concentration. After
all of the serum was added to the tubes in triplicate, the samples were put on a tube rotator
for 20 hours.
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Table 3. NP specifics for 20-hour protein exposure
NP Type

Average hydrodynamic
size (d.nm)

Mass required for surface
area goal (mg)

PLGA-FGF

346.43

0.59

PLGA-PEG-FGF

250.0

0.77

Alginate-FGF

389.0

0.57

Alginate-PEG-FGF

286.97

0.75

Table 4. Protein isotherm experiment setup with varying protein concentrations
Tube Number

Protein Concentration (mg/mL)

Volume of Serum
added to Tube (μL)

1

0

0

2

0.1

2.01

3

0.25

5.04

4

0.5

10.12

5

1

20.37

6

1.5

30.76

30

7

2

41.30

8

3

60.81

9

4

97.12

10

5

107.70

After 20 hours of exposure, the samples were centrifuged for 1 hour at 15,000 g at
RT. The supernatants from each tube were aliquoted, and a BCA assay was run to
determine how much free protein existed within the solution. The pellet consisting of
particles and adsorbed protein was resuspended in 0.1 mM PBS. Once all tubes had their
particles resuspended, another BCA assay was run on an aliquot of each tubes’ contents to
show how much protein was actually adsorbed to the particle surface. Since tube 1 was just
nanoparticles, the absorbance value for this sample was used as the “blank” to ensure the
final absorbance value is strictly from the protein present in solution and not any NPs. After
the BCA assay was completed, size and zeta potential were read on the zetasizer for all
resuspended particles with adsorbed protein to see how the protein was affecting the
particle’s surface characteristics. A detailed representation of this protocol can be seen in
section 7.2 as Figure 36. For the isotherm visualization, the concentration of protein on the
resuspended particles was graphed versus the concentration of protein that was in initially
in solution. This graph can be seen for each particle type in Figures 29-30.
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CHAPTER 3: RESULTS AND DISCUSSION
3.1 Particle Synthesis
Particles were synthesized by several techniques, with and without the addition of
PEG, to examine the interactions of particles with proteins in mouse serum. Different
synthesis techniques and materials were expected to lead to particles differing in
morphology, size, zeta potential, and interactions with proteins. Therefore, particles were
first thoroughly characterized using various methods including SEM, DLS, and
electrophoretic DLS before protein studies were completed. The emulsion techniques used
throughout these experiments yielded particles with uniquely different morphology when
imaged with SEM. The PLGA and PLGA-PEG NPs were definitively spherical with
relative uniformity across the field of view, whereas particles from the Alginate and AlgPEG samples were hard to identify via SEM. As expected from literature, the PLGA and
PLGA-PEG NPs varied slightly in size between the individual particles, but their
morphology was nearly uniformly spherical, as seen in Figures 10 and 11 [51]. Upon visual
inspection, the PLGA-PEG particles were more uniform than the PLGA-FGF NPs that
were not coated in PEG. The SEM images of the PLGA-PEG-FGF NPs also looked very
similar to SEM images of PEG-PLGA particles that were synthesized by Mohan et al. for
investigating the effects of PEG on enhanced drug targeting. The particles created by
Mohan et al. had an average size of 312 nm, a PDI of 0.41, and a zeta potential of -20.97
mV [52]. All of these values were very similar to the PLGA-PEG-FGF NPs synthesized
in this thesis work. Interestingly enough, the PDI value for the PLGA-PEG-FGF NPs was
higher than that of the PLGA-FGF NPs, as seen in Table 5. However, the reported size of
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the PLGA-PEG-FGF NPs was about 60 nm smaller than the PLGA-FGF NPs, which
suggested that the PEG acted as a stabilizer in the emulsion synthesis. The use of PEG has
been widely researched, specifically for coating NPs, and since PEG is very hydrophilic, it
can act as a coating that stabilizes the colloid [53]. Kasim et al. found that the use of PEG
as a coating for silver NPs reduced and stabilized them in solution. Additionally, using
DLS, they found that the PDI values of PEG-coated silver NPs were lower than the
uncoated silver NPs, which implied a more uniform size distribution [54]. Similar results
of these effects of PEG were also obtained by Shiba at el. as they used PEG within their
protocol for the synthesis of Prussian blue NPs. Their use of PEG allowed for more uniform
NPs to be fabricated, as there was more dispersion and reduction of surface interactions
amongst the particles [55]. The PLGA-PEG particles followed these trends throughout the
experiments, and overall were the most invariant type of NP synthesized within this
project.
Table 5. DLS and DLS electrophoretic measurements of purchased and synthesized
materials
NP

Average Hydrodynamic size
(d.nm)

Average PDI

Average Zeta
Potential (mV)

Mouse serum

133.60

0.46

-26.03

20 nm Au

29.22

0.12

-36.80

PLGA-FGF

346.43

0.21

-12.26

PLGA-PEGFGF

282.70

0.53

-26.48

Alg-FGF

229.07

0.410

-57.11

Alg-PEG-FGF

272.17

0.37

-58.13
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When comparing the PDI values of the synthesized particles, it was important to
note the PDI of the 20 nm Au NPs. These NPs were purchased from Sigma Aldrich, which
is a manufacturer; knowing that the PDI of these particles was 0.12 allowed for a healthy
comparison for the size distribution and uniformity of the particles synthesized with the
emulsion techniques. Table 5 demonstrates an instance where the use of PEG with alginate
created slightly larger, but more uniform particles compared to the non-PEGylated alginate
particles, as denoted by the smaller PDI value. Alalaiwe et al. discovered similar effects of
PEG in regard to an increase in particle size compared to uncoated particles as they
investigated the effects of PEG on oral bioavailability of Au NPs in rats [56]. Other studies
conducted by Elsewedy et al. have reported that the use of PEG on brucine-loaded PLGA
NPs slightly increased the size of the particles while decreasing their PDI. They also found
that the use of PEG could increase particle size and slightly increase PDI, depending on
the molecular weight of the PEG used in synthesis [57].
The Alginate and Alg-PEG NPs were much harder to image using SEM, likely due
in part to particle instability during drying and melting under the electron beam during
imaging. Figures 8 and 9 show the lack of defined spherical presence of NPs, which were
incredibly abundant in the PLGA and PLGA-PEG SEM images. The figures below may
not have fully captured the true Alginate and Alg-PEG NP structure due to the method of
sample preparation for SEM or imaging error. Conversely, stable size readings on the
zetasizer with moderate PDI values were achieved, suggesting that the samples were
composed of NPs and not stable during drying or imaging. In the future, the particle
samples should incorporate a cryoprotectant to minimize this instability. When comparing
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these SEM images to those in literature, they were similar in the sense that the NPs were
not as clear and appeared to be a part of a larger material. Daemi and Barikani investigated
alginate and calcium ion concentrations to see how these variables affected the synthesized
particles in regard to their size distributions. Their SEM images appeared similar to the
SEM images of the Alginate and Alginate-PEG particles obtained in this thesis research
[58]. Additionally, it has been observed by Thai et al. that alginate-based NPs that are in
the size range of 100-200 nm have a tendency to agglomerate together to form larger
particles that are on the micro scale [59]. This is likely what was seen in Figures 8 and 9.
Other studies conducted by Fan et al. have successfully captured clean, spherical alginatebased NPs in their SEM photos, but this is likely to be material and synthesis methoddependent, since both of these factors affect the size and surface characteristics of the
particles [60]. The Alg-PEG SEM images contained more definitive spherical particles
compared to the non-PEGylated Alginate NPs, which can be seen in Figures 8 and 9, and
in Figure 38 in the Supplemental Materials section.
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Figure 8. SEM of Alg-FGF NPs with a scale bar of 400 nm

Figure 9. SEM of Alg-PEG-FGF NPs with a scale bar of 400 nm
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Figure 10. SEM of PLGA-FGF NPs with a scale bar of 400 nm

Figure 11. SEM of PLGA-PEG-FGF NPs with a scale bar of 400 nm
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3.2 Protein Exposure
3.2.1 Initial Experiments; 3 Hours for Alg-FGF, Alg-PEG-FGF, PLGA-FGF, and
PLGA-PEG-FGF NPs
While later experiments allowed us to conclude that these shorter-term protein
exposure experiments had a variety of flaws, including unrealistic particle concentrations
in solution and an interrupted equilibrium, these studies formed the basis for the more
thorough adhesion experiments discussed later. Figures 12 and 13 show the lack of trends
over time as the protein and NPs were interacting. As highlighted in the Methods and
Materials section, an aliquot of 50 μL of all of these samples was taken and mixed with
950 μL of DI water to create a volume of sample that was large enough to use with DLS;
this was unintentionally adding more volume to the sample being read, which likely altered
the equilibrium of adhesion at the particle’s surface. The average hydrodynamic size results
seen below were valid for what existed within the capillary tube that was placed within the
zetasizer, but they likely did not represent what was happening within the samples that
were on the tube rotator due to the introduction of additional water before reading samples.
Jansch et al. reported that when exposing ultrasmall superparamagnetic iron oxide particles
to plasma protein, the change in particle size seen after 0.5 and 240 minutes were similar
both qualitatively and quantitatively. This finding supports that a protein corona forms
around the particles and is in fact long-lived, or “hard” [61]. Due to the nature of how this
experiment was carried out, a hard corona was never identified based on size measurements
because the samples were altered before being read. These results and challenges in their
initial analysis were the impetus to the more thorough protein isotherm experiments in
section 3.2.4 below.
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Figure 12. Plot of Average hydrodynamic size for PLGA-FGF and PLGA-PEG-FGF NPs
when exposed to serum protein for less than 3 hours

Figure 13. Plot of average hydrodynamic size for Alg-FGF and Alg-PEG-FGF NPs when
exposed to serum protein for less than 3 hours
The figures above do not include error bars because the plotted points are an
average of the 3 readings that the DLS completes in one singular calculation round. If the
standard deviation of those 3 readings were to be calculated and plotted then the error on
the plot would really just be the deviation of the instrument, not the deviation over the
whole sample. If this experiment were repeated, including error bars that represent the
variation of the particles themselves by reading 3 separate samples at each time point for
the particle being exposed to protein would be a more rigorous approach. This would allow
for a standard deviation to be calculated since there would be 3 individual readings from 3
completely different vials, all of which have particles and proteins from the same sample.
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This idea was repeatedly discussed throughout the protocol setup of this work, but handling
experiment and instrument reading time impeded this approach. Since the zetasizer took
12 minutes to complete size and zeta potential readings, there was already a wide gap
between triplicate readings, and it was impossible to compare these data points in a
statistically rigorous way. There are multiple different avenues that someone might take in
order to avoid the issues experienced within this mini protein exposure experiment; these
ideas are discussed in Chapter 4.
With the samples being incidentally diluted, the size results for this experiment
did not lead to any strong conclusions about protein adsorption over the span of 2.5 hours.
However, the dilution that occurred before reading on the zetasizer did not appear to affect
the zeta potential results of the particles. As seen in Figures 14 and 15, as exposure time to
protein increased, 3 of the 4 particle types showed that the charge of the particles tended to
decrease. This is a common theme within literature as well; Li et al. investigated the effects
of serum albumin on PLGA NPs and found that as protein adsorbed to the surface of the
particles, the surface charge of the particles became less negative [62]. The constant
fluctuations between points on the figures below could be due to the dilution step that
occurred, or agglomeration within the sample.
Interactions between NPs in solution is quite common but can be harmful to the
experiment. The movement of synthesized NPs can increase collision frequency, which
leaves them temporarily attached to one another, forming particle agglomerates. These
agglomerates lead to poor morphological stability that can abate the activity of the particles
[63]. This process is reversible, but it is possible that some particles will cluster and not be
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able to be separated again; this irreversible interaction is called aggregation [64]. NPs are
very prone to interacting with one another because of their small sizes, which lead to high
surface energies. As particles form these clusters, their surface energy decreases and their
size increases, affecting the particle’s physicochemical properties, transport, and
biodistribution [65], [66]. Agglomeration, aggregation, and sedimentation were a common
issue that was faced throughout this thesis work. In an attempt to keep all samples under
the same conditions, as samples were prepared for DLS they were all minimally vortexed
for the same amount of time. Originally, the particles were sonicated anytime that they
needed to be dispersed within a liquid, but this created a handful of issues as particles
started falling out of solution and having very high PDI values when size measurements
were being taken (specifically for Alginate NPs). It is hypothesized that adding the
additional energy from the sonicator into the sample was increasing the number of surface
interactions amongst the particles, causing them to form agglomerates and aggregates. To
avoid the intense addition of energy into the sample, the samples were vortexed instead.
The vortexing only lasted 10 seconds, which was long enough to ensure that the sample
being read was thoroughly mixed. Pradhan et al. investigated the effects of sonication on
NP dispersion and found that when sonication increased the number of aggregates formed
in solution, sedimentation of the NPs rapidly occurred. Sedimentation can negatively
impact an experiment because the concentration within the solution is affected.
Sedimentation also dramatically increases the PDI of the sample, making it more difficult
to characterize the NPs [67].

41

Figure 14. Plot of zeta potential for PLGA-FGF and PLGA-PEG-FGF NPs when exposed
to mouse serum protein for less than 3 hours

Figure 15. Plot of zeta potential for Alg-FGF and Alg-PEG-FGF NPs when exposed to
mouse serum protein for less than 3 hours

3.2.2 Adsorption Isotherm Experiment; 22 Hours with Varying Concentrations of Au
NPs
To address the possibility that the previous protein exposure experiments were
not obtaining results that were truly showing the adsorption that was taking place, a new
exposure experiment was created that was based on tens of hours of exposure. This new
protocol took into consideration the issues with the volume requirements for DLS, which
meant that there had to be much more volume involved in this setup to avoid the dilution
step before reading samples. This first round of over 20 hours of protein exposure aimed
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to highlight how differing concentrations of NPs reacted with the same volume of protein
to find an ideal ratio of particles to protein. To set this up, a dilution series of 20 nm Au
NPs was created. This dilution series was then read on the spectrophotometer at 525 nm to
ensure the accuracy of the concentration gradient, which would be denoted by the amount
of light absorbed by each sample [68], [69]. The absorbances of the samples are shown in
Table 6. Stable 20 nm Au NPs provided from the supplier at 1 OD should have an
absorbance value very close to 1.0 for their peak at 525 nm. This is not seen in this graph
because the wells were only filled one third of the volume upon reading. Once this mistake
was realized, the values were multiplied by 3 to account for the two thirds of the well that
were not filled. Additionally, the particles used in this experiment were remeasured after
the experiment was completed with the proper volume in the well and they had an
absorbance value of about 0.97, indicating that they were in fact stable. Importantly in
Table 6, the first 5 samples show a decrease in absorbance, which supports that the samples
had fewer NPs as the sample number increased. For samples 6-10, these tubes were so
diluted that the absorbance readings were very close to that of water; this was expected
since each sample had been diluted 10 times more than the sample before it. Upon visual
inspection, samples 6-10 did not look any different from one another, whereas samples 15 had a nice gradient of red to light pink to blush.
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Table 6. Reading absorbance of samples 1-10 at 525 nm to demonstrate a NP concentration
decrease

Sample

Average
Absorbance at
525 nm

Standard
Deviation

1

0.778

0.003

2

0.083

0.002

3

0.01

0.003

4

0.002

0.002

5

0.001

0.003

6

0.002

0.002

7

0

0.002

8

0.001

0

9

0.001

0

10

0

0.002

After 22 hours of protein exposure, the particles were collected and resuspended
in 0.01 mM PBS to simulate a biologically relevant pH. The particle size was read using
DLS. For comparison, a sample named “5 control” was created at the beginning of this
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experiment and treated like every other sample. This sample consisted of the same
concentration of NPs as sample 5, but it did not contain any protein. As seen in Figure 16,
there was over a 200 nm difference in the size readings for sample 5 and 5 control. Since
the concentration of particles was the same in both samples, these results showed that the
presence of protein had a large impact on the agglomeration of NPs. DLS reported the
average size of the Au NPs used in this experiment to be roughly 27 nm. Particles this small
would not be reading over 400 nm in size if they were not agglomerating. Hinkley et al.
observed this same occurrence when using 23 nm Au NPs for investigating the rates of oral
absorption within mice. Their study found that particles without PEG formed agglomerates
that measured several hundred nm in diameter [70]. Figure 16 also shows an increase in
the standard deviation of the samples as the particle concentration decreases. This was
likely due to the lack of particles within the sample, which made it harder for the instrument
to get consistent readings. The error bars also show how for sample 1A, there is very little
error. The error increased once protein was introduced to the samples, and then fluctuated
as the number of particles in each sample decreased.
The far left of Figure 16 shows DLS measurements taken of NPs and mouse serum
protein alone. This data was included in this graph as a means to emphasize how under
individual conditions, a material suspended within solution can read a certain size, but
when it is introduced to a mixture with another material—like protein—the DLS
measurements can completely change. Sample 10A did not have any NPs in it and was just
composed of DI water and protein, making it similar to the second orange bar sample on
the far left of the graph. Upon visual inspection these 2 bar heights are about 25 nm
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different from each other, demonstrating the reproducibility of the protein sizes using DLS
when the sample is just composed of protein and water. Alternatively, the lack of
correlation between particle concentration and size seen in samples 4-9 indicated that this
experiment needed to be refined.

Figure 16. DLS size of resuspended 20 nm Au NPs after 22 hours of protein exposure with
varying NP concentrations

Additional studies were conducted to collect the zeta potential measurements of the
resuspended particles, in addition to the protein concentrations for the supernatants of the
samples and the resuspended particles. However, these results are not included here
because they did not help clarify any of the surface interactions that this experiment set out
to identify. Especially after seeing the size results for the resuspended particles, it was
evident that the particles had behaved differently depending on their concentrations within
solution. This led to the creation of a very similar protocol to this one, except the protein
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would be varied instead of the nanoparticles to rule out any potential changes in protein
adsorption that were due to particle concentration alone.
3.2.3 Adsorption Isotherm Experiment; 22 Hours with Varying Concentrations of
Protein (Au NPs)
Knowing that varying the concentration of the NPs present in solution caused
additional variables to be introduced into the protein adsorption kinetics informed this
subsequent experimental approach. The concentration of NPs was held constant while
varying amounts of protein, which meant that the kinetics would be primarily driven by
the amount of protein present in solution. The experiment detailed in this section was
approached as a proof-of-concept, so only 4 samples were used. Protein concentration
decreased from samples A1 to C1, and D1 was a control with no protein. All alphabetized
samples had the same concentration of NPs, which allowed for direct comparison of
adsorption results. The first values analyzed were the DLS measurements of the
resuspended particles. As seen in Figure 17, as protein concentration within solution
decreased, the average size of the particles decreased as well. These results were expected
because as less protein existed in solution, fewer interactions between protein and particle
surface would be expected to take place, causing less effect on NP size. Size can be used
as an indirect measurement of protein adsorption, assuming that the particles without
protein were measured for comparison [71]. Figure 17 includes DLS measurements for
diluted 20 nm Au NP stock, as well as sample D1, which has the same concentration of
NPs as samples A1-C1 but without protein. The diluted stock and D1 were both about 36
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nm in size, whereas samples A1-C1 were all over 66 nm. These results indicated that there
was a direct positive correlation between protein concentration and NP size in solution.

Figure 17. DLS size of resuspended 20 nm Au NPs measured by DLS after 22 hours of
protein exposure with varying protein concentrations; protein concentrations shown in
graph inset
The zeta potential measurements of the resuspended particles reiterated the findings
that had previously been seen with the 3-hour protein exposure experiments; as protein
bound to the surface of negatively charged particles, the NP’s surface charge became less
negative, as has previously been reported in literature [62]. Figure 18 demonstrates this
finding with every sample that was exposed to protein for 22 hours. The orange bar shows
the zeta potential of the stock 20 nm Au NPs, which were stored in the refrigerator, per
manufacturer recommendations, until analysis. Samples A1-C1 all contained protein, and
all had zeta potential readings that were less negative than the stock particles’ values. As
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previously mentioned, as agglomeration occurs, particles experience a decrease in their
surface energy [63]. It is hypothesized that the zeta potential for D1 was less negative than
the stock particles because the D1 particles had been on a tube rotator for 22 hours, which
increased the collision frequency within solution. Increased collision frequencies lead to a
higher probability of forming agglomerates and aggregates, which affect the surface
activity of the particles [63], [65], [66]. Even though D1 and the diluted NP stock solution
both consisted of just NPs and DI water, they had been under different conditions for those
22 hours. Au NPs are more stable when stored at 20 degrees Celsius, compared to being
left out at RT, as higher temperatures can affect NP properties [72]. Samples A1-D1 in
Figure 18 confirmed that protein interaction at the surface decreased the NP’s surface
potential in a manner that was concentration-specific.

Figure 18. Zeta potential of resuspended 20 nm Au NPs after 22 hours of protein exposure
with varying protein concentrations
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These results of protein concentration-dependent surface modification of NPs were
also supported by the BCA assay that was run on the resuspended particles to determine
the concentrations of protein present. Figure 19 definitively shows how less protein in the
sample resulted in less protein adsorbing to the NP surface. Between the DLS and BCA
assay results, this experiment was successful as a proof of concept; at this point, we
proceeded to conduct this experiment with a wider, value-specific range of protein
concentrations and with the synthesized NPs instead of purchased stock.

Figure 19. Protein concentration on resuspended 20 nm Au NPs after 22 hours of protein
exposure with varying protein concentrations

3.2.4 Adsorption Isotherm Experiment; 20 Hours with Varying Concentrations of
Protein (Synthesized NPs)
Using all of the results gathered up to this point, the final protein exposure
experiment was designed, lasting 20 hours and completed using the polymeric particles
synthesized as drug delivery vehicles within this work instead of the purchased 20 nm Au
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NPs. PLGA-FGF, PLGA-PEG-FGF, Alg-FGF, and Alg-PEG-FGF NPs were all exposed
to mouse serum protein using the same methods.
Tables 7, 8, 9, and 10 show the protein concentrations, standard deviations, and
the associated error that existed within samples 1-10 for each of the particles exposed to
protein. Even though the mouse serum protein concentrations were created using the same
volumes for each sample number across all 20-hour experiments, it was evident that there
was a wide range in the percent errors for the protein used in the exposure for each type of
particle. The micro BCA assay used for protein detection only had a working range up to
200 µg/mL, which meant that samples 3-10 had to be diluted 100:1. Due to this dilution,
the assay’s results for these tubes were multiplied by 100, as was the standard deviations
of the readings. This was why tubes 1-2 for each type of particle exposure had very small
standard deviations and percent errors compared to the rest of the samples. It was
hypothesized that the dilution step was partially responsible for why some of the samples
had higher standard deviations and percent error values compared to others. Ideally, the
protein concentrations would have been much closer to the intended protein for each
sample tube; however, since the same volume of protein serum was used for each
respective sample for all synthesized particle exposure experiments these error values did
not dictate the validity of the experiment. Instead, they represented how difficult it was to
create a specific concentration using serum. Serum itself is not a singular protein, but
instead is composed of a variety of proteins that all have different physical, chemical, and
physiological properties [73]. The variation of proteins that existed within the serum could
have also been responsible for the difference between the true and intended protein
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concentrations due to sampling differences or errors. Regardless, the serum was mixed
thoroughly before each use, and definitive volumes were added per sample number. Since
this method was repeated for all particle types, the error shown in the tables was not a large
concern.
It might seem logical to have used a different protein assay that had a larger working
range so that any error that occurred would not then be multiplied by 100; however, a
micro-BCA assay kit needed to be used because there were very small amounts of protein
in sample 2, as well as within the resuspended particle samples seen in Figures 29-31.
While doing these experiments, uniformity was strived for, which was why the same
protein assay was used throughout all sample readings, even if the samples had to be
diluted. For more ideas on how to address this potential error/misreading of protein present
in the samples due to dilution, please refer to Chapter 4. As a whole, the protein
concentrations in tubes 1-10 increased for all 20-hour experiments, which effectively
allowed for particles in samples 1-10 to be exposed to different amounts of proteins. For
the goals of these experiments, having larger deviations and percent errors was not too
concerning since all sample values showed a distinct increase in protein concentration from
the previous sample number, which allowed for the whole dataset to span a wide range of
protein concentrations to which the particles were exposed.
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Table 7. Percent error of protein concentrations in each sample for 20-hour PLGA-FGF
NP exposure to protein
Theoretical
Measured
Percent Error
Standard
Protein
Protein
(MeasuredDeviation
Sample
Concentration Concentration
Theoretical) /
(mg/mL)
(mg/mL)
(mg/mL)
(Measured)*100
1

0

0

0

0

2

0.10

0.16

0.004

38.82

3

0.25

0.60

0.250

58.54

4

0.5

0.87

0.294

42.46

5

1.0

1.35

0.325

26.09

6

1.5

1.97

0.427

23.82

7

2.0

2.62

0.377

23.63

8

3.0

3.79

0.357

20.82

9

4.0

5.87

0.682

31.85

10

5.0

6.27

0.745

20.22
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Table 8. Percent error of protein concentrations in each sample for 20-hour PLGA-PEGFGF NP exposure to protein

Sample

Theoretical
Protein
Concentration
(mg/mL)

Measured
Protein
Concentration
(mg/mL)

Standard
Deviation
(mg/mL)

Percent Error
(MeasuredTheoretical) /
(Measured)*100

1

0

0

0.003

0

2

0.10

0.11

0.004

10.71

3

0.25

0.45

0.288

44.69

4

0.5

0.76

0.390

33.77

5

1.0

1.23

0.299

18.70

6

1.5

1.71

0.311

12.49

7

2.0

2.21

0.309

9.67

8

3.0

3.32

0.421

9.61

9

4.0

4.60

0.281

13.01

10

5.0

5.43

0.486

7.92
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Table 9. Percent error of protein concentrations in each sample for 20-hour Alg-FGF NP
exposure to protein

Sample

Theoretical
Protein
Concentration
(mg/mL)

Measured
Protein
Concentration
(mg/mL)

Standard
Deviation
(mg/mL)

Percent Error
(MeasuredTheoretical) /
(Measured)*100

1

0

0

0.004

0

2

0.10

0.098

0.005

-2.15

3

0.25

0.47

0.395

47.12

4

0.5

0.78

0.401

35.82

5

1.0

1.40

0.401

28.37

6

1.5

1.95

0.406

23.20

7

2.0

2.53

0.421

20.82

8

3.0

3.51

0.421

14.60

9

4.0

5.50

0.442

27.22

10

5.0

6.07

0.412

17.59
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Table 10. Percent error of protein concentrations in each sample for 20-hour Alg-PEGFGF NP exposure to protein

Sample

Theoretical
Protein
Concentration
(mg/mL)

Measured
Protein
Concentration
(mg/mL)

Standard
Deviation
(mg/mL)

Percent Error
(MeasuredTheoretical) /
(Measured)*100

1

0

0

0.002

0

2

0.10

0.14

0.003

26.19

3

0.25

0.49

0.233

49.39

4

0.5

0.81

0.237

38.61

5

1.0

1.50

0.248

33.22

6

1.5

2.06

0.232

27.31

7

2.0

2.69

0.237

25.73

8

3.0

3.80

0

20.99

9

4.0

5.34

0.247

25.03

10

5.0

5.85

0.250

14.50
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PLGA-FGF and PLGA-PEG-FGF NPs demonstrated opposite size trends when
exposed to protein. As the protein concentration in solution increased, the PLGA-FGF
particles decreased in size, whereas the PLGA-PEG-NPs increased in size, as seen in
Figure 20. The non-PEGylated PLGA-FGF NPs were likely stabilized by the proteins in
solution, which decreased the amount of agglomeration occurring compared to the samples
that had very minimal amounts or even no protein present, which can be seen on the left
side of the plot in Figure 20. The size readings for PLGA-FGF NPs with zero protein were
over 1000 nm after 20 hours of tube rotation, while the most concentrated protein sample
read just over 270 nm, which was close to the typical size for these particles. McKenzie et
al. found similar effects of protein on the agglomeration of polystyrene NPs; their work
demonstrated that the incubation of NPs with protein decreased the size and PDI values of
their particles. They concluded that this was due to the soft corona—which is a short-term
layer with a low affinity—of proteins that covered the particles, which decreased the selfagglomeration of the NPs. The polystyrene NPs that were incubated without any proteins
had much larger size and PDI values, likely due to their lack of surface coatings that the
protein had provided for the other particles [74], [75]. The R2 value for the PLGA-FGF
NPs was not very high, but the equation still indicated that there was a weak negative
correlation between particle size and protein concentration.
The PLGA-PEG-NPs showed a strong increase in size as the protein concentration
increased. Since the particles were already coated in PEG, they likely started off more
stable than the uncoated PLGA particles; this allowed for the particles to have a smaller
size reading after the 20 hours of tube rotation, comparatively, which was only about 560
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nm. The first sample of PLGA-PEG-FGF NPs that contained protein had an even smaller
size than the sample without protein, measuring about 208 nm. As the protein concentration
increased, the particle size also increased, eventually measuring 793 nm in the most
concentrated protein sample. The R value for this plot was 2.5 times higher than the PLGA2

FGF particles, which indicated that the PEG coating allowed for stronger particle size
predictions as protein concentrations increased, compared to uncoated PLGA particles.
Studies conducted by Dąbkowska et al. found that PEGylation improved colloidal stability
of dendrimer NPs via steric repulsion, which facilitated more dispersion of the NPs within
solution [76], [77]. Sorret et al. also investigated the use of PEGylation and established
that it aided in a decrease in aggregation of proteins [78]. Using these two studies for
comparison, it was hypothesized that the use of PEG with PLGA particles allowed for more
NP dispersion within solution and less particle-particle agglomeration and aggregation,
both of which lead to an increase in particle-protein interactions as more surface area was
available for proteins to adsorb to. The effects of PEG on the size distribution of the sample
were also demonstrated in Figure 24. The PDIs were similar for both PLGA-based NPs,
but the PDI for the sample without protein was slightly less for the PLGA-PEG-FGF NPs
than the PLGA-FGF NPs. Furthermore, the standard deviations of the PDIs were much
larger for the non-PEGylated NPs, as seen by the error bar size on the PLGA-FGF NP plot
in Figure 24.
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Figure 20. Plot of hydrodynamic size for PLGA-FGF and PLGA-PEG-FGF NPs after 20
hours of mouse serum exposure with varying concentrations of protein
Both alginate-based NPs showed an increase in the particle size as the concentration
of protein in solution increased. Figure 21 shows how both the Alg-FGF and Alg-PEGFGF NP samples without protein had nearly the same particle size after 20 hours of tube
rotation, which was about 600 nm. The effects of PEG appeared to be more relevant once
protein was introduced into the samples. Both particle types had very similar upward trends
and R values for their plots, but the PEGylated alginate particles had slightly smaller size
2

values for samples 1-10 compared to the Alg-FGF NPs. Interestingly enough, the tubes
with the highest protein concentrations for Alg-FGF and Alg-PEG-FGF were very close in
size; the Alg-FGF NP final size reading was 548 nm and the Alg-PEG-FGF NP final size
reading was 532 nm.
Another important aspect of this experiment was the standard deviation of both
alginate samples. The average standard deviation for the PEGylated NPs was 10 nm less
than the Alg-FGF NPs. Patsula et al. showed that PEG created antifouling properties for
NPs that were administered into mice, which allowed for a prolonged circulation time and
an increased biodistribution [79]. The antifouling properties of PEG have repeatedly led to
a decrease of surface interactions amongst NPs and their surrounding environments [80].
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The addition of PEG in the Alg-PEG-FGF NPs was likely responsible for the decreased
standard deviations seen since there were less interactions that took place on the particle's
surface; less surface interactions naturally led to a smaller size distribution of particles
compared to the non-PEGylated NPs. This concept was further supported by the PDI values
seen in Figure 23. For samples 1-10, the average PDI for the Alg-PEG-FGF NPs was about
0.04 less than the PDI for the Alg-FGF NPs. When looking only at the samples that range
from 0-1 mg/mL, the average PDI for the Alg-PEG-FGF NPs was 0.07 less than the AlgFGF NPs. After 1 mg/mL the majority of the sample size PDIs were either 1 or very close
to 1, likely due to the large additional presence of the proteins, which dramatically affected
uniformity of the sample.

Figure 21. Plot of hydrodynamic size for Alg-FGF and Alg-PEG-FGF NPs after 20 hours
of mouse serum exposure with varying concentrations of protein
Figure 22 shows all synthesized particle sizes after 20 hours of protein exposure.
The PLGA-FGF NPs showed the largest change in particle size and the Alg-FGF NPs
showed the smallest change in particle size as the protein concentration increased. The
PLGA-PEG-FGF NPs showed an increase of 240 nm while the Alg-PEG-FGF NPs showed
an increase of 160 nm from sample 1 to sample 10. Both PEGylated particles showed
positive and negative size trends between individual samples from samples 1-10, but both
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ended up slightly larger in size than they started. Based on these results, the PEG particles
appeared more stable and predictable in size over a large range of protein concentrations
compared to the PLGA-FGF and Alg-FGF NPs. Depending on the ideal size of a
therapeutic treatment and the protein environment in which the particles would be
targeting, the Alg-PEG-FGF particles would be recommended if larger sizes were
acceptable. If smaller particles were required, then the PLGA-PEG-FGF NPs would be a
promising NP for treatment based on their predictable protein adsorption kinetics.

Figure 22. Plot of all hydrodynamic sizes for synthesized NPs after 20 hours of mouse
serum exposure
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Figure 23. Plot of PDI values for size readings of Alg-FGF and Alg-PEG-FGF NPs after
20 hours of mouse serum exposure

Figure 24. Plot of PDI values for size readings of PLGA-FGF and PLGA-PEG-FGF NPs
after 20 hours of mouse serum exposure
For all of the NPs exposed to protein, three out of the four types showed an initial
decrease in PDI as protein was added to the sample (seen at 0.1 mg/mL), likely due to the
stabilization that the protein provided for the particles. After these data points, all particle
types showed a general increase in PDI as more protein was added to the sample, as seen
in Figures 23 and 24. This trend was expected because as more proteins existed in solution,
there was an increase in the probability of interactions amongst the proteins and particles,
as well as proteins with other proteins. Each protein has its own unique critical
concentrations, at which point aggregation occurs [81]. Spontaneous aggregation of mouse
serum protein has been reported to increase as protein concentration increases, supporting
that large clusters of particles and proteins were more likely to occur in the samples that
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had higher protein concentrations [82]. Larger clusters within the sample would have
caused the PDI to increase, which is clearly seen by the data points to the far right of the
plot in Figure 25.

Figure 25. Plot of all PDI values for size readings of synthesized NPs after 20 hours of
mouse serum exposure
The zeta potential measurements of all synthesized particles after 20 hours of
protein exposure were uniquely different from the trends seen in the previous NP exposure
experiments. Alg-PEG-FGF NPs were the only type of particles that showed an overall
increase—or less negative value—in zeta potential when comparing sample 1 to sample
10, as seen in Figures 26 and 28. All of the other synthesized particles experienced a
decrease in zeta potential as the protein concentration increased. Figure 27 shows how there
was not a definitive trend for the zeta potential for the PLGA-PEG-FGF NPs as the
concentration of protein increased, and the zeta potential for the most concentrated sample
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was more negative than the sample without protein. NPs that have a zeta potential of +/30 mV are considered stabilized [83]. Neither of the PLGA-based sample 1 NPs had a zeta
potential that was more negative than -30 mV after 20 hours of tube rotation, indicating
that the particles were no longer very stable. In past studies, the zeta potential of PLGA
particles was read directly after the particles were synthesized; these results indicated that
the PLGA-FGF and PLGA-PEG-FGF particles had zeta potentials of -12 mV and -26 mV,
respectively. These results also indicated that particles started the experiment not being
very stable, although the PEGylated NPs were close to the cutoff. However, the changes
seen with these zeta potential measurements cannot be directly compared to the past studies
because those were completed with 20 nm Au NPs, which had a more negative zeta
potential than these PLGA particles. The Au NPs used in the previous experiments had a
zeta potential of -37 mV, and the mouse serum used throughout these experiments had a
zeta potential of -26 mV. Based on the protein interactions on the surface of NPs
investigated by Li et al., as protein binds to a particle, the surface charge of that NP changes
depending on the difference between the NP’s charge and the protein’s charge [62].
Because the protein in the serum was more negative than the PLGA-based particles, protein
that bound to the NP surface actually made the surface more negative because the new zeta
potential of the NP surface was driven by its protein corona [84]. The past exposure studies
saw a decrease in zeta potential as protein bound to the surface because the protein was
less negative than the Au NPs, but that was not the case for the PLGA particles.
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Figure 26. Plot of zeta potentials for Alg-FGF and Alg-PEG-FGF NPs after 20 hours of
mouse serum exposure

Figure 27. Plot of zeta potentials for PLGA-FGF and PLGA-PEG-FGF NPs after 20 hours
of mouse serum exposure

Figure 28. Plot of all zeta potentials for synthesized NPs after 20 hours of mouse serum
exposure
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After the particles had been on the tube rotator for 20 hours, they were centrifuged
to collect a NP pellet. The protein concentration within the supernatant and on the
resuspended NPs was assessed using a micro-BCA protein assay kit. Lee et al. previously
reported that centrifuging particles after protein exposure did not result in a significant
protein depletion from the solvent, which they demonstrated with an absorbance spectral
scan of the supernatant [86]. These results were verified by reading the protein
concentrations of solution before and after 1 hour of centrifugation at 15,000 g at RT, which
is what the protein would be subjected to during the real experiment with NPs. These results
indicated that the resuspended NP protein concentration value was representative of only
the protein adsorbed to the surface of the particle and was not being afffected by protein
that had fallen to the bottom of the tube due to centrifugation.
When plotting the protein concentration readings for all 20-hour exposure
experiments, error bars were not included in the graphs because the errors were so large
that the actual data points appeared to be in one straight line due to the magnitude that the
error bars made the y-axis increase by. The error bars were so much larger than the actual
data point values due to the 100:1 dilution that took place for the readings, which made the
error for each reading also multiplied by 100. Instead, the error values can be seen in Tables
11, 12, 13, and 14 for all of the particles exposed to protein. Not including the error bars in
the plots allowed for a closer look of the trends of the data points, which were modeled
using a polynomial with an order of 2. A linear model was considered for the data, but the
polynomial model had the highest R2 value for all particle types, which can be seen in
Figures 29, 30, 31, and 32 for all particle types exposed to protein. An exponential and
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power model were also considered, but these were not able to be used since the data was
not exclusively composed of non-zero values.
Table 11. Protein concentrations and associated standard deviations for all PLGA-FGF
samples for the 20-hour protein isotherm experiment
Sample

Initial Protein
Concentrations in
Sample (mg/mL)

Concentration of
Protein on
Resuspended
Particles (mg/mL)

Standard Deviation
of Protein on
Resuspended
Particles

1

0.0

0.0

0.0

2

0.163

0.010

0.001

3

0.603

0.020

0.002

4

0.869

0.044

0.004

5

1.353

0.078

0.007

6

1.969

0.120

0.008

7

2.619

0.323

0.082

8

3.789

0.560

0.061

9

5.869

1.016

0.194

10

6.267

1.463

0.431

The protein concentration correlation shown in Figure 29 for PLGA-FGF NPs had
the highest R2 value for all of the polymeric NPs exposed to protein. All of the R2 values
were above 0.95 for the calculated models, which indicated that the graphed protein
concentrations were all well-defined and predictable by the polynomial equation related to
each dataset [87]. As seen in the past 3-hour and 22-hour adsorption experiments, the
PLGA-FGF NPs in this study reiterated that as more protein existed in solution, more
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surface interactions took place, which increased the protein concentration on the particle.
Figure 29 demonstrates the noticeable difference in the NP’s protein concentration when
the particles were exposed to less than 1 mg/mL of protein compared to when they were
exposed to over 3 mg/mL.
It was hypothesized that the concentration of protein adsorbed to the surface of
the NPs would level off after a material-specific concentration was reached in solution if
the isotherm had been modeled using a Langmuir or Freundlich approach, which was
commonly reported in other protein isotherm experiments [86]. For graphing the raw data
of adsorbed proteins compared to the concentration of proteins in solution, Yallapu et al.
reported similar plots to the ones seen in Figures 29 and 30 as they investigated the
physicochemical effects of human serum on magnetic nanoparticles. As their percent
concentration of human serum in solution increased (up to 50%), the percent of adsorbed
protein onto the NP surface had also increased [88]. However, the effects of PEG on the
PLGA-based NPs synthesized in this work were incredibly evident, even if there was no
indication of the adsorption leveling off. The highest concentration of adsorbed protein on
the PLGA-FGF NPs was 1.463 mg/mL, while the highest concentration on the PLGAPEG-FGF NPs was only 0.757 mg/mL. This data supported the previously described
effects of PEG, specifically related to its ability to decrease the amount of NP surface
interactions that take place [15], [18]. As fewer surface interactions take place, less protein
adsorbs to the surface, which is apparent when comparing the values in the second and
third columns of tables 11 and 12. Even though each numbered sample tube had the same
volume of protein added across all 20-hour experiments respectively, the PEGylation of
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the NPs was able to decrease the protein-particle interactions, especially for samples 6-10,
which had much higher concentrations of protein compared to the first half of the samples
for the non-PEGylated NPs. The models used to visually represent the protein adsorption
seen in Figures 29, 30, 31, and 32 only represent the adsorption for the given initial protein
concentration range, but not for any values beyond the max initial protein concentrations.
Figures 29 and 30 are not indicative of an exponential protein adsorption for PLGA-based
particles with all possible protein concentrations; the fits chosen for these graphs were the
ones with the smallest R2 values for the given range of data. Future work should be
completed for all tested particles to identify if the adsorption responses seen here are
repeatable, as well as representative of these particle’s true interactions with protein.

Figure 29. Protein isotherm model for PLGA-FGF NPs with varying protein
concentrations after 20 hours of protein exposure; y = 0.0301x2+0.0248x-0.0011 with an
R2 = 0.9785
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Table 12. Protein concentrations and associated standard deviations for all PLGA-PEGFGF samples for the 20-hour protein isotherm experiment
Sample

Initial Protein
Concentrations in
Sample (mg/mL)

Concentration of
Protein on
Resuspended
Particles (mg/mL)

Standard Deviation
of Protein on
Resuspended
Particles

1

0.0

0.0

0.003

2

0.112

0.010

0.003

3

0.452

0.017

0.003

4

0.755

0.035

0.005

5

1.230

0.067

0.005

6

1.714

0.287

0.0

7

2.214

0.305

0.287

8

3.319

0.394

0.312

9

4.598

0.553

0.351

10

5.430

0.757

0.300
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Figure 30. Protein isotherm model for PLGA-PEG-FGF NPs with varying protein
concentration with 20 hours of NP and protein exposure; y = 0.0029x2+0.1217x-0.0195
with an R2 = 0.9674
The Alg-FGF and Alg-PEG-FGF NPs demonstrated the leveling off of adsorbed
protein that was expected to occur, as seen in Figures 31 and 32, particularly at about 5-6
mg/mL of protein present in solution. The difference in polynomial modeling seen with the
alginate-based NPs compared to the PLGA-based NPs could be due to the differences in
surface charge, amongst other material properties. Interestingly enough, the PEGylated
alginate particles did not show a pronounced difference in protein adsorption compared to
the non-PEGylated particles. As previously discussed, this could have been due to the
protein stabilizing the Alg-FGF NPs, which created a much different surface dynamic for
the free protein in solution to interact with [89]. Both alginate-based NPs had very similar
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protein adsorption kinetics and were both modeled by a polynomial equation that had an
R2 value of 0.96 when rounded. The Alg-FGF and Alg-PEG-FGF NPs also demonstrated
that as more protein existed in solution, more surface interactions took place, leading to a
higher concentration of protein adsorbed onto the surface of the NP.
Table 13. Protein concentrations and associated standard deviations for all Alg-FGF
samples for the 20-hour protein isotherm experiment
Sample

Initial Protein
Concentrations in
Sample (mg/mL)

Concentration of
Protein on
Resuspended
Particles (mg/mL)

Standard Deviation
of Protein on
Resuspended
Particles

1

0.0

0.0

0.004

2

0.098

0.010

0.004

3

0.473

0.023

0.005

4

0.779

0.041

0.009

5

1.396

0.427

0.389

6

1.953

0.445

0.395

7

2.526

0.553

0.405

8

3.513

0.656

0.435

9

5.496

0.761

0.436

10

6.067

0.929

0.392
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Figure 31. Protein isotherm model for Alg-FGF NPs with varying protein concentration
with 20 hours of NP and protein exposure; y = -0.022x2+0.2822x-0.0418 with an R2 =
0.9553
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Table 14. Protein concentrations and associated standard deviations for all Alg-PEG-FGF
samples for the 20-hour protein isotherm experiment
Sample

Initial Protein
Concentrations in
Sample (mg/mL)

Concentration of
Protein on
Resuspended
Particles (mg/mL)

Standard Deviation
of Protein on
Resuspended
Particles

1

0.0

0.0

0.004

2

0.135

0.011

0.006

3

0.494

0.020

0.005

4

0.815

0.037

0.008

5

1.498

0.414

0.416

6

2.064

0.447

0.424

7

2.693

0.602

0.402

8

3.797

0.596

0.421

9

5.336

0.893

0.558

10

5.848

1.049

0.384
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Figure 32. Protein isotherm model for Alg-PEG-FGF NPs with varying protein
concentration with 20 hours of NP and protein exposure; y = -0.0108x2+0.2389x-0.0355
with an R2 = 0.9568
For all of the synthesized NPs, the PLGA-PEG-FGF NPs had the least amount of
protein adsorbed onto their surface, comparatively. Even though this particle type had the
highest reported PDI value out of all of the particles, it continued to be the most predictable
and followed the anticipated trends reported in literature, specifically in regard to material
behavior and protein adsorption kinetics.
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CHAPTER 4: FUTURE WORK
In the common nature of science, there are always new decisions to be made for
how experiments should be run. These decisions tend to heavily depend on the previously
acquired results, as well as how clean the logistics of the experiments were. Typical options
for experiment refinement in regard to this thesis work were either experiment modification
for the gain of cleaner results or testing new methods found in literature to gain an
understanding of the current results. Both of these options aided in the common goal of
acquiring a complete set of data that highlighted the nature of protein adsorption kinetics
on the synthesized polymer NPs. Even with these decisions that were made to arrive at
desired results, there are still countless directions in which the next experiments could go.
To address the issue of direct time point comparison that did not exist between the
triplicate samples when exposed to mouse serum for less than 3 hours (Figures 12 and 13),
the setup of the experiment would need to be adjusted. A simple fix for this could be to
expose a singular triplicate—i.e. A—to protein on 1 day and get size and zeta potential
readings every 12 minutes for that triplicate. The next day, triplicate B could be exposed
to protein and readings could be taken at the same time points as they were for triplicate
A. On day 3, triplicate C could be exposed to protein and readings could be taken at the
same time points as the A and B readings. This would take three days instead of just one,
but it would allow for more data points over the span of the 3 hours. The 3-hour exposure
completed in this thesis work had only about 4-5 data points because when all of the
triplicates were exposed to protein at the same time, there was a 45-minute time block
between when one triplicate would get read on the zetasizer and the next time that it was
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able to be read again. If only one triplicate was exposed to protein in a day, this would
allow for about 15 data points over the span of 3 hours instead of just 5; this would clearly
be a much more complete set of data that could demonstrate very fine changes, compared
to the data previously acquired. Alternatively, this experiment could be completed in one
singular day, but in order to have the ability to directly compare the size and zeta potential
readings at the same time points, the triplicates would need to be offset in their initial
protein exposure start times. This would make this experiment longer than 3 hours overall.
There would also be a heavy reliance on the zetasizer to work properly and not take any
extra time to read samples, which commonly occurred during these past studies.
Additionally, doing all of the protein exposure in one day would require a very strict
regimen for having the samples prepared to be read at the exact time necessary. Based on
the experience gained in this thesis work, it seems more likely that something would go
wrong trying to make this a 1-day experiment instead of a 3-day experiment, if the goal is
to have the same time points for direct comparison between triplicates of one type of NP,
in addition to comparison across other types of NPs.
The 3-hour protein exposure experiment also had a potential equilibrium issue that
needed to be addressed, which is why the 20–24-hour protein isotherm experiments were
created. However, if the 3-hour exposure experiment were to be revisited, the volume of
nanoparticles used would need to be increased due to the volume required for the DLS
readings. The previous experiment set up only utilized 50 µL of volume from the NP and
protein exposure solution. Using only 50 µL and mixing it with 950 µL of DI water was
unintentionally putting the NPs present in solution into a new environment that was not at
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an equilibrium. This could have led to new protein adsorption kinetics taking place, which
did not represent what was actually happening within the solution that was on the tube
rotator. In order to have readings that were representative of the NP and protein
interactions, 1000 µL of the sample should be used for the size and zeta potential readings.
Additionally, free protein within the sample could affect the validity of the size and zeta
potential results since the goal of the readings was to see how the particles themselves were
being affected by the protein on their surface. To address this, the volume taken from the
mixing solution should be filtered or otherwise manipulated so that the readings only reflect
data that is true for just the particles that have adsorbed protein, and not for the free protein
and free particles with some protein on them that exist within the solution. Free protein
posed a large problem with the uniformity of the sample readings, which is typically
denoted by the PDI value of the size result. As more protein existed within the solution,
the PDI would increase, which naturally had an associated size value that did not feel
incredibly trusting, given what was in the sample. This growth in PDI value as protein is
added to solution is very evident in Figure 25. Looking into ways to decrease the PDI for
the protein exposure samples would be useful for collecting size readings that are more
exemplary of the size of the NPs that have adsorbed protein rather than just free protein
and agglomerated NPs that exist within the sample.
In respect to the characterization of the NPs synthesized within this work, SEM was
able to be performed, in addition to DLS, for size readings of the particles. As previously
mentioned, the DLS readings could have easily been reporting sizes that were not entirely
accurate for the given population of singular NPs in solution, especially within the samples
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that contained particles and an abundance of agglomeration due to insufficient dispersion
or the presence of protein. One characterization method that would be beneficial to combat
the agglomeration issue would be nanoparticle tracking analysis (NPTA). The average size
results of NPTA would likely be less than the zetasizer readings because NPTA is more
known for its ability to look at individual particles rather than particles throughout the
entirety of a sample, which could possibly be agglomerated or falling out of solution. DLS
addresses every type of object within the sample in the capillary tube and creates an overall
average size, whereas the NPTA calculates size on a particle-by-particle basis. NPTA is
known for performing well with both mono- and polydisperse samples; in fact, it has been
highlighted that the presence of larger particle groups within solution do not compromise
the accuracy of the measurements given [90]. A complete set of data was not able to be
acquired for the four different types of NPs synthesized within this work, so having NPTA
completed for each of these NPs would aid in understanding the true size of the particles,
which has a direct tie to their protein adsorption kinetics. The results of this completed
thesis work could also be further interpreted if there were more known characteristics
regarding the NPs’ physical compositions. Multiple materials went into the synthesis of
these NPs, so being able to identify how each one of those affects the NP’s final size, shape,
and charge would be meaningful for being able to predict how the NPs would react with
certain proteins and/or other bodily responses when exposed within the body. Additional
methods of characterization that could be considered are transmission electron microscopy
(TEM), mass spectrometry, and X-ray diffraction, all of which would give additional
results related to NP size, shape, and structure.
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The NPs synthesized within this work were done so in a way to encapsulate FGF2; however, the encapsulation efficiency of these techniques was not explored. Further
work could be done to break down the NPs and release the FGF-2 to run a BCA assay on
the encapsulated protein. By comparing the concentration of encapsulated protein to the
initial starting volume, one could see how effective the w/o and w/o/w techniques were at
encapsulating this growth factor. This data could be incredibly helpful for understanding
how many NPs would be necessary to deliver a certain volume of drug that is required to
have the intended impact at a delivery site. If work is done to validate that the FGF-2 was
in fact successfully encapsulated, these NPs could be used for other types of drug deliveries
as well. For example, dexamethasone could be the encapsulated drug instead of FGF-2.
Dexamethasone is a synthetic steroid and has been known for its anti-inflammatory
properties, as well as its anti-allergy and immunosuppressive nature. In the past it has been
used to treat prophylaxis and chemotherapy-induced nausea [91]. This is just a singular
example of a drug that could be encapsulated and used to treat common diseases that
revolve around inflammation, which are heavily prevalent within the United States [92].
Seeing what other drugs are able to be encapsulated with emulsion techniques would open
up a wide realm of possibilities for these synthesized particles and their potential
applications.
As protein adsorption took place onto these synthesized NPs, it was very evident
that the surface characteristics of the NPs were altered. Some other next steps of this work
in regard to using these particles as cancer treatment could be to expose different particle
sizes—size change due to different amounts of protein adsorbed—to endothelial cells and
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monitor the cellular uptake. It would be beneficial to know how the adsorption of the
protein to a certain size NP affects the NP’s ability to get inside of a cell with those proteins
on its surface, which is what it would need to do for it to deliver the therapeutic drug and
carry out its intended mechanism of action. Staying with this same line of thought, it would
also be advantageous to research how protein adsorption kinetics change with varying NP
size. The work done within this thesis used group averages for size and protein exposure,
so the overall results are speaking broadly of the synthesized NPs; however, it would be
neat to be able to discuss if there is actually a preferred size of NP that has the most
predictable protein adsorption kinetics. Knowing these types of results could be used for
altering the emulsion protocols to synthesize NPs with an intended size that are more easily
characterized when it comes to their surface protein interactions.
Throughout the completed experiments, one singular micro-BCA assay was used
for all protein measurements within the isotherm experiments. The assay detection was
only able to measure up to 200 µg/mL, which meant that many different types of samples
had to be diluted 100 times in order to get the protein present in solution within the working
range of the assay. This allowed for the same working reagent to be used for all samples,
but it also dramatically increased the errors and standard deviations of some results due to
some sample stats needing to be multiplied by 100. To avoid diluting samples as often, a
regular BCA kit could be used with these experiments, which has a detection of up to 2
mg/mL. For the initial protein concentrations within solution, the range spans from 0 to 5
mg/mL, so if there were to be no diluting of samples, an assay with a very wide range of
detection would need to be used. One potential solution to this could be a Qubit Protein
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Assay kit, which has a quantitation range of 12.5 µg/mL to 5 mg/mL [93]. Using this type
of kit would allow for all measurements to be completed using the same assay without any
dilutions, which would decrease overall error and standard deviation seen across all
samples, and therefore increase the preciseness of the results being reported for the
concentrations of protein present within solution and on the NPs.
The protein concentration data collected using the micro-BCA assay for the
concentration of protein initially in solution and in the supernatant after 20 hours of particle
exposure was not able to be used for a Langmuir protein isotherm graph of qe versus Ce.
The model data points for qe, which represent the concentration of adsorbate on the
particles when the experiment is finished, would have been defined by the following
!"∗$%

equation: 𝑞𝑒 = 𝑞𝑚𝑎𝑥 ∗ &'!"∗$%. In this equation, qmax is the absolute max possible
protein concentration of adsorbate that could be on the surface of the particles at
equilibrium, KL is the Languir equilibrium constant, and Ce is the quantity of adsorbate
that remains in solution after equilibrium is reached. For the raw qe data, which would be
compared to the model qe data, qe would be equivalent to Co minus Ce, all divided by the
mass of the particles [94]. The protein results from the 20-hour experiments indicated that
some of the samples had more protein in solution after the full particle exposure time than
there originally was in the experiment setup. FGF-2 was encapsulated inside of the particles
used for this set of experiments, which could have been introduced into the sample solution
if the PLGA and alginate particles had degraded. Studies conducted by Su et al. have found
that encapsulated drugs within PLGA particles can take an average of 15 days for total
release time, suggesting that the FGF was likely not the main reason for the increase in
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protein concentration in solution [95]. Factors that can influence particle degradation
include water permeability, pH, molecular weight, monomer ratio, and the polymer’s
hydrophobicity/hydrophilicity [96]. It has also been reported that the use of too much PEG
on the NP surface could lead to degradation due to its detergent-like properties that increase
membrane permeability and premature drug release [97], [98]. To rule out the possibility
that FGF had influenced the final protein concentration readings, an experiment could be
conducted that mimics the 20-hour exposure methods, but does not include the addition of
mouse serum protein. Reading the initial protein concentration in each sample tube of just
NPs, which should be 0 mg/mL, and reading the final protein concentration after 20 hours
of tube rotation would reveal if any FGF had actually been released from the particles due
to degradation.
It was hypothesized that the final protein concentration was slightly higher than the
initial protein concentration in solution strictly due to the error introduced into the
experiment from diluting the samples 100:1. The samples that did not have to be diluted
had final supernatant concentrations that were less than the starting protein concentrations
in solution; the samples that had to be diluted were about 30 mg/mL higher in
concentration. Out of the 9 samples that contained protein, only 4 of them—2 of which
were tubes that did not need to be diluted for the assay reading—had final supernatant
protein concentrations that were less than the initial starting protein concentrations.
Because the majority of the samples showed larger concentrations of protein in the
supernatants after 20 hours, the isotherm graphing that was supposed to be used for analysis
was not able to be conducted as planned. The protein adsorption experiment setup and
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isotherm graphs that were initially going to be used for analysis were inspired by past
isotherm studies published by Meissner et al. and Lee et al. with minor modifications [71],
[86]. To be able to complete the intended graphical analysis, a protein assay kit should be
used that allows for the samples to be read exactly as they exist without any diluting. This
could be solved by using the Qubit Protein Assay kit, as previously described. Between the
use of a new assay kit and testing for particle degradation, it is believed that the original
plan of isotherm plotting of qe versus Ce will be able to be achieved and will highlight the
true isotherm characteristic of these particles and their associated protein adsorption
kinetics.
For all 20-hour protein exposure experiments the particles were suspended in 0.1
mM PBS because PBS has a biologically relevant pH of approximately 7.4 [99]. However,
it is important to acknowledge the effects that pH has on particles, proteins, and particleprotein interactions. During these studies, PBS was used to simulate healthy body tissue
pH’s that the NPs would initially exist in if delivered intravenously. However, if these
particles were to be used for tumor treatment and exist within a tumor microenvironment,
they would eventually experience a more acidic pH of approximately 6.8 compared to
healthy tissue [100]. It has been hypothesized that a more acidic environment allows for an
increase in cell migration due to the involvement of actin-binding proteins [101]. The
change in pH towards more basic values of 4-5 has been reported by Sotnikov et al. to
create a saturated monolayer of proteins on Au NPs. They also found that more neutral and
alkaline values of 7-10 increased adsorption and allowed for polylayers of proteins that are
not saturated on the particle surface [102]. Although the synthesized particles in this work
84

would initially experience a neutral pH if injected intravenously for therapeutic application,
further studies should be completed to investigate the effects of altered pHs on the rates of
the protein adsorption. In addition to changing the pH of the suspension solution before
protein exposure, it would also be encouraged to study the effects of starting at a neutral
pH for protein exposure and then moving the particles and protein into a more acidic pH
to identify the changes in the particle-protein interactions. Acquiring these results would
allow for a more representative data set to be presented and discussed in a manner that is
more relevant for drug delivery application.
The above points were the main ideas that were pondered while crafting these
experiments, however, there are always new ways to look at situations and strategize for
an even better outcome. The possibility of someone new taking over this work is very
exciting as fresh eyes tend to see things with a new lens, allowing for newfound approaches
for problem solving and discovery.
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CHAPTER 5: CONCLUSIONS
Protein adsorption within the body defines a NP’s efficacy as a therapeutic drug
delivery agent. Being able to measure adsorption kinetics and fit to a predictive model
allows for an increased understanding of the interactions that NPs will experience when
administered in vivo. This work has demonstrated the protein interactions that take place
at the surface of a variety of polymeric NPs, as well as the effects that this adsorption has
on the characteristics of the NP. PLGA-FGF, PLGA-PEG-FGF, Alg-FGF, and Alg-PEGFGF NPs were synthesized and exposed to mouse serum, verifying the ability of PEG to
decrease protein interaction at the particle surface. Additionally, this work highlighted that
the effects of protein adsorption on NP surface charge are dependent on the individual
charges of the NP material and protein. The comprehensive results of this thesis work
create a foundation for protein adsorption on polymeric NPs and its associated effects,
which can be used to aid in the development of encapsulating drug delivery technology.
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CHAPTER 7: SUPPLEMENTAL MATERIAL
7.1 Emulsion Protocols

Figure 33. Detailed w/o protocol used to make alginate-FGF and alginate-PEG-FGF NPs

95

Figure 34. Detailed w/o/w protocol used to make PLGA-FGF and PLGA-PEG-FGF NPs
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7.2 NP Exposure to Mouse Serum

Figure 35. Detailed NP exposure to mouse serum and associated zetasizer readings
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Figure 36. Detailed 20-hour NP exposure to varying concentrations of mouse serum
protein ranging from 0-5 mg/mL
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7.2 SEM Images

Figure 37. SEM image of Alg-FGF NPs with a scale bar of 20 μm
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Figure 38. SEM image of Alg-PEG-FGF NPs with a scale bar of 400 nm

Figure 39. SEM image of Alg-PEG-FGF NPs with a scale bar of 2 μm
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Figure 40. SEM image of Alg-PEG-FGF NPs with a scale bar of 20 μm

Figure 41. SEM image of PLGA-FGF NPs with a scale bar of 2 μm
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Figure 42. SEM image of PLGA-PEG-FGF NPs with a scale bar of 30 μm
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